Comparison of urokinase and tissue plasminogen activator for thrombolysis in rats.

A comparison of human recombinant tissue-type plasminogen activator and urokinase in microsurgical thrombolysis in the rat.

Tissue plasminogen activator in peripheral arterial thrombolysis.

Thrombolysis with low dose tissue plasminogen activator.

Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.

Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis.

Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?

Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.

Urinary and kidney cell plasminogen activator (urokinase).

Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.

Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.

Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.

Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia.

Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2.

urokinase plasminogen activator receptor mRNAs.

Endovascular thrombolysis for pediatric cerebral sinus venous thrombosis with tissue plasminogen activator and abciximab.

Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.

Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.

Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.

Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.

Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration.

Presence of urokinase-type plasminogen activator (u-PA) in tissue extracts of antrochoanal polyp.

Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis.

Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis.

Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.

Suggest Documents

A comparison of human recombinant tissue-type plasminogen activator and urokinase in microsurgical thrombolysis in the rat.

Tissue plasminogen activator in peripheral arterial thrombolysis.

Thrombolysis with low dose tissue plasminogen activator.

Bio-responsive delivery of tissue plasminogen activator for localized thrombolysis.

Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis.

Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?

Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.

Urinary and kidney cell plasminogen activator (urokinase).

Hyperglycemia is associated with lower levels of urokinase-type plasminogen activator and urokinase-type plasminogen activator receptor in wound fluid.

Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.

Soluble urokinase-type plasminogen activator receptor and urokinase-type plasminogen activator receptor contribute to chemoresistance in leukemia.

Urokinase vs Tissue-Type Plasminogen Activator for Thrombolytic Evacuation of Spontaneous Intracerebral Hemorrhage in Basal Ganglia.

Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2.

urokinase plasminogen activator receptor mRNAs.

Endovascular thrombolysis for pediatric cerebral sinus venous thrombosis with tissue plasminogen activator and abciximab.

Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.

Differences in the reactivities of human urokinase and the porcine tissue plasminogen activator.

Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis.

Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial.

Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration.

Presence of urokinase-type plasminogen activator (u-PA) in tissue extracts of antrochoanal polyp.

Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis.

Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis.

Different receptors mediate the hepatic catabolism of tissue-type plasminogen activator and urokinase.

Comparison of urokinase and tissue plasminogen activator for thrombolysis in rats.

Recommend Documents

Follow Us